Rivaroxaban Market, By Strength (10 mg, 15 mg, and 20 mg), By Application (Deep Vein Thrombosis Prophylaxis and Pulmonary Embolism), By Distribution Channel (Hospital Pharmacies, Retail Pharmaciesand Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa) - Trends, Analysis and Forecast till 2029

Report Code: PMI7618 | Publish Date: March 2024 | No. of Pages: 168

Global Rivaroxaban Market By Strength Overview

Rivaroxaban is an anticoagulant, and the oral factor Xa inhibitor, indicated for prevention of venous thromboembolic events (VTE) for patients undergone total hips replacements, knee replacement surgery, prevention of stroke and cardiovascular &heart attack in coronary artery disease (CAD)or symptomatic peripheral artery disease (PAD) patients.  

Growing incidence of cardiovascular disease cases positioned major operating players in this market to launch an effective medication in the market. Further, increasing number of hip and knee replacement surgeries, worldwide; combined with higher efficacy of rivaroxaban in treatment regime will spur the demand for rivaroxaban in near future.

Increasing number of research and development (R&D) activities in the field of rivaroxaban expected to drive the market. For instance, In July 2018, Bayer received the positive- Committee for Medicinal Products for Human Use (CHMP) opinion in a new indication of its Xarelto (rivaroxaban). The Xarelto 2.5 mg is indicated to use for the prevention of atherothrombotic events in adult patients with Coronary Artery Disease (CAD) or symptomatic Peripheral Artery Disease (PAD). This positive opinion is based on data from the COMPASS study, which is the largest phase III study done with rivaroxaban, showed that rivaroxaban 2.5 daily dose effectively reduces risk of stroke, cardiovascular death and heart attack by 24% in patients with PAD and CAD.    

The rivaroxaban market has been segmented on the basis of strength, application, distribution channel and region.

On the basis of strength, the rivaroxaban market is segmented into 10 mg, 15 mg and 20 mg. Further, on the basis ofapplication, the rivaroxaban market is segmented into deep vein thrombosis prophylaxis and pulmonary embolism. Distribution channel for rivaroxaban market includes hospital pharmacies, retail pharmacies and online pharmacies. 

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is expected to dominate the rivaroxaban market, owing to an increased awareness regarding possible risk factors in cardiovascular disease & stroke, and high ability to spend on healthcare expenditures, will spur the growth of rivaroxaban market in the future. 

Key players operating in the rivaroxaban market include Bayer AG, Janssen Pharmaceuticals Inc., Dr. Reddy's Laboartories Ltd., Taj Pharmaceuticals Limited and Anant Pharmaceuticals Pvt. Ltd.

Global Rivaroxaban Market By Strength Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
    • PORTER’s
    • Investment Outlook
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for Rivaroxaban Strategies
      • Key Questions this Study will Answer
      • By Strength (10 mg, 15 mg, and 20 mg)

        By Application (Deep Vein Thrombosis Prophylaxis and Pulmonary Embolism)

        By Distribution Channel (Hospital Pharmacies, Retail Pharmaciesand Online Pharmacies) 

        By Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)

    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Overview
    • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
    • Y-o-Y Growth Analysis (%), 2020 – 2030
    • Regional Trends
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Regional Analysis
    • Regional Revenue Analysis
    • Regional By segment Analysis
    • Reasons for regional growth
    • Key Player of particular region
    • Countries Include in the report:
  1. North America (U.S., Canada)
    • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)
    • Latin America (Brazil, Mexico, Rest of Latin America)
    • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
    • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
    • Competitive Overview
    • Competitive Benchmarking
    • Market Share Analysis
    • Key Developments In The Rivaroxaban Market
    • Key Developments: Mergers & Acquisitions
    • Key Developments: Collaboration
    • Key Developments: Contracts & Agreements
    • Key Developments: Expansion
    • Key Developments: Product Developments
  2. Company Profiles
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
  • SWOT Analysis
    • Bayer AG 

    • Janssen Pharmaceuticals Inc. (Johnson & Johnson).

  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The rivaroxaban market has been segmented on the basis of strength, application, distribution channel and region.

Emerging trends include the increasing use of rivaroxaban in various therapeutic indications, the development of novel formulations, and the exploration of its applications in extended prophylaxis. Opportunities arise from the growing prevalence of cardiovascular and thromboembolic disorders, advancements in anticoagulant therapy, and the expanding applications of rivaroxaban in different patient populations.

Key factors include the rising incidence of atrial fibrillation, deep vein thrombosis, and pulmonary embolism, the need for effective and convenient anticoagulant options, and the advantages of direct oral anticoagulants (DOACs) like rivaroxaban in terms of dosing and monitoring. Additionally, the increasing adoption of oral anticoagulants in place of traditional therapies contributes to market growth.

Regions covered include North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the market due to a well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and significant adoption of anticoagulant therapies. However, the Asia-Pacific region is experiencing notable growth, driven by increasing healthcare awareness, rising incidences of thromboembolic disorders, and the expansion of pharmaceutical markets in countries like China and India.

Key players operating in the rivaroxaban market include Bayer AG, Janssen Pharmaceuticals Inc., Dr. Reddy's Laboartories Ltd., Taj Pharmaceuticals Limited and Anant Pharmaceuticals Pvt. Ltd.